Publications by authors named "Purevsuren Batsaikhan"
Background: Data on changes in pneumococcal serotypes in hospitalised children following the introduction of the pneumococcal conjugate vaccine (PCV) in low-income and middle-income countries are scarce. In 2016, Mongolia introduced the 13-valent PCV (PCV13) into the national immunisation programme. We aimed to describe the trend and impact of PCV13 introduction on pneumococcal carriage in hospitalised children aged 2-59 months with pneumonia in Mongolia over a 6-year period.
View Article and Find Full Text PDFArticle Synopsis
- A study assessed the long-term effects of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal carriage in infants and toddlers in Asia, with surveys conducted before (2015) and after (2017, 2022) its introduction.
- The findings revealed a decrease in carriage of PCV13 serotypes and a drop in resistance genes among toddlers six years after the vaccine was introduced, although overall pneumococcal density increased.
- The most common non-vaccine serotype identified in 2022 was Serotype 15A, mainly linked to a specific genetic lineage, suggesting that tracking these changes is vital for future vaccine development.
Starting in June 2016, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the routine immunization program of Mongolia by using a 2+1 dosing schedule, phased by district. We used prospective hospital surveillance to evaluate the vaccine's effect on pneumonia incidence rates among children 2-59 months of age over a 6-year period. Of 17,607 children with pneumonia, overall adjusted incidence rate ratios showed decreased primary endpoint pneumonia, very severe pneumonia, and probable pneumococcal pneumonia until June 2021.
View Article and Find Full Text PDFImpact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia hospitalisations in Mongolia: a time series analysis.
Lancet Reg Health West Pac
March 2024
Background: Few studies have assessed the potential indirect effects of childhood pneumococcal conjugate vaccine (PCV) programs on the adult pneumonia burden in resource-limited settings. We evaluated the impact of childhood PCV13 immunisation on adult all-cause pneumonia following a phased program introduction from 2016.
Methods: We conducted a time-series analysis to assess changes in pneumonia hospitalisation incidence at four district hospitals in Mongolia.
Article Synopsis
- Community-acquired pneumonia is a significant health issue globally, especially in low- and middle-income countries, where its impact on adults is under-studied.
- A study analyzed over 4,000 respiratory admissions in Ulaanbaatar, finding that severe pneumonia primarily affects older adults and is more common in men and individuals with existing health issues.
- From 2015 to 2018, the incidence of pneumonia in adults increased, with the highest rates observed in those aged 65 and older, highlighting the need for targeted vaccination and prevention strategies.